Chemomab Therapeutics (NASDAQ:CMMB) Trading Up 16.2% – Should You Buy?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) rose 16.2% on Thursday . The company traded as high as $2.01 and last traded at $1.99. Approximately 179,159 shares traded hands during trading, an increase of 1% from the average daily volume of 177,277 shares. The stock had previously closed at $1.71.

Wall Street Analyst Weigh In

Separately, Oppenheimer restated an “outperform” rating and set a $11.00 price objective (down from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th.

Chemomab Therapeutics Stock Up 16.2 %

The firm’s 50 day simple moving average is $1.62 and its 200 day simple moving average is $1.43. The company has a market cap of $28.57 million, a price-to-earnings ratio of -1.99 and a beta of 0.66.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Sphera Funds Management LTD. acquired a new position in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned 8.46% of Chemomab Therapeutics as of its most recent SEC filing. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).